Macrophage regulation of tumor responses to anticancer therapies.

By Michele De Palma, C. Lewis. Cancer Cell, 2013

1,063 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/8f97b505bc648151b1a53bb2223439db6e8f3f13

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Mantovani
2. A. Sica
3. P. Allavena
4. J. Pollard
5. R. Noy
6. Xiangming Zou
7. Yan-Cun Liu
8. Yong-ming Yao

In Molecular Biology

1. A. Mantovani
2. A. Sica
3. P. Allavena
4. J. Pollard
5. R. Noy
6. Xiangming Zou
7. Yan-Cun Liu
8. Yong-ming Yao

Citations in the corpus

• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “These studies reflect a growing paradigm that the tumour stroma plays an important role in therapy resistance [150, 154, 156, 157].”
• Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, neutral): “We investigated innate immune cells because they are found in the KP tumor stroma (Cortez-Retamozo et al., 2012) and might be modulated by drugs to induce tumor control (Broz and Krummel, 2015; De Palma and Lewis, 2013).”
• The interaction of anticancer therapies with tumor-associated macrophages (2015, background): “…for red pulp macrophages (Kohyama et al., 2009), and an increased understanding of the epigenetic landscape of resting and activated macrophages (De Santa et al., 2007; Ostuni et al., 2013; Gosselin et al., 2014; Lavin et al., 2014) will likely pave the way to an increased understanding of…”
• Macrophage Polarization in Inflammatory Diseases (2014, background): “TAM modulates the efficiency of chemotherapy, radiation therapy, and vascu-lar-targeted therapies with monoclonal antibodies and immunotherapy in different stages of various tumors [81] .”
• Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, positive): “exerting a cytotoxic effect, several chemotherapy drugs modulate macrophage responses to tumor [157,158].”
• Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “latory T cells (Tregs) and tumor associated macrophages (TAMs) have been associated with pro-tumor functions [1–3], whereas CD8 T cells have been associated with”
• Drug resistance and combating drug resistance in cancer (2019, background): “Macrophages secrete high levels of colony stimulating factor-1 (CSF-1) in GBM tumors, supporting cancer cell proliferation and survival([115,116]).”
• Tumor-associated macrophages: from mechanisms to therapy (2014, background): “Several recent studies suggest that such an approach is feasible and therapeutic (Coussens et al., 2013; De Palma and Lewis, 2013).”
• Tumor-associated macrophages: from basic research to clinical application (2017, background): “DNA damage, cell death, and increased hypoxia have been observed in tumors after radiotherapy, which has been shown to lead to macrophage recruitment and promote tumor progression in animal models [81].”
• The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment (2020, background): “Given these two activated states, macrophages are regarded as “a double-edged sword” with both pro-tumor and anti-tumor ability [47, 48].”